Kazia Therapeutics Ltd lands trifecta of licensing deals in March quarter, leaving it "a vastly stronger and more substantial business"
Kazia Therapeutics lands trifecta of licensing deals in March quarter, leaving it "a vastly stronger and more substantial business" During the quarter, the oncology-focused drug development company saw maiden revenue of A$5.3 million and its cash position increased to A$19.7 million end-March. These transactions leave Kazia a vastly stronger and more substantial business, with a diversified pipeline of world-class oncology assets. Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9M) has kicked off 2021 with a trifecta of March quarter licensing deals, leaving it "a vastly...